Transcript Slide 1
ProteoNova™ Inc. Overview © 2008 ProteoNova™, Inc. The Company ProteoNova is a biotechnology company located in Pasadena, California. The Company has developed a platform technology that …. .… accelerates the development of novel proteins for therapeutic and diagnostic uses, and …. …. has broad applications – including for humans, livestock, and crop plants. Next The Technology The Company has patented novel methods that…. …. use a proprietary DNA library…. …. link proteins with their coding messages…. …. use accelerated protein evolution and specialized selection techniques…. …. to rapidly and inexpensively make novel protein products. Next Potential Markets The technology can be used to develop products in the following categories: • Human Pharmaceuticals • Vaccines • Diagnostics • Veterinary Drugs • • • • Biowarfare Agriculture Enzymes Industrial Chemicals Next How the Technology Works An illustration of the Company’s overall approach for generating novel proteins…. Next Protein Evolution in Practice DNA Library ProteoNova Selection Technologies Enriched and selected cDNAs Translated mRNA pool Optimize Selected cDNAs by error prone PCR Translated Protein Test for functional activity Next ProteoNova’s Proprietary DNA Library Linker 3’ 5’ • The reading frame of the oligos in the library is random. • The library is extremely large, > 1x1014 different sequences. • It is biased to produce hydrophilic proteins. • The library produces proteins ~100 amino acids long. • The sequences in the library are labeled with a light activatable linker. Next The Linker Technology In Vitro transcription/ translation Light activatable cross linker on last codon of the mRNAs from proprietary DNA library Protein 5’ Puromycin tRNA Complex 5’ mRNA 3’ 5’ 360nm Light activates the linker, and thereby, crosslinks the mRNA with the ultimate tRNA Ribosome The modified mRNA occupies the last codon and accepts the protein thus forming an mRNA-tRNA-Protein complex Next ProteoNova’s Various Linker Methods Methods In vitro translation 360 nm irradiation Complex Puromycin on 3’ Linker on anticodon Linker on anticodon Puromycin on 3’ Linker on mRNA Linker on mRNA Next Selection Process Purify the protein and configure for preclinical testing Transcribe/translate the library using ProteoNova’s linker technology DNA Library 3’ 5’ linker Protein-tRNA-mRNA complex Bioreactor culture Target molecule Introduce the DNA into host cells or organism Real time PCR of cDNA Reverse transcribe mRNA to cDNA using reverse transcriptase, nucleotides and primers Protein-tRNA-mRNA complexes reacted with Target molecule affixed to solid substrate, i.e.. magnetic beads c-DNA Taq DNA Polymerase Taq DNA Polymerase Next Pre-Clinical Testing Months 0 1 2 3 4 5 Phase I 7 8 9 Phase II In vitro testing In vivo testing in animals Transcribe/translate library • • • • 6 select for product make enough for testing test in vitro a viable product expected within three rounds of selection Product that tests efficacious in vitro is then tested in vivo in animal model(s) • a viable product expected within two rounds of selection Pre-clinical testing Rnd 1 Rnd 2 Rnd 3 Rnd 1 Rnd 2 Next Intellectual Property Three U.S. patents have been issued Six patent applications are pending in the U.S. The Company has a patent issued in Australia, and patents pending in the EU, Japan, Hong Kong and Canada The ProteoNova, Inc. name is trademarked in the U.S. and is a registered trademark in the EU Next Summary ProteoNova’s technology is a powerful platform technology that harnesses the power of accelerated protein evolution and in vitro mRNA and tRNA display to greatly simplify production of novel proteins. It dramatically reduces the time, labor and cost for producing proteins with specific properties. The system can be used to create effective vaccines, more sensitive and specific diagnostics, and virtually any therapeutic where antibodies are currently used. The technology is protected with a broad patent portfolio. Next Contact Information For further information, please direct queries to: Robert Guerrero, Ph.D. CEO ProteoNova, Inc. 814 South Euclid Avenue Pasadena, California 91106 Telephone: Facsimile: E-mail: 626-793-9970 626-795-2599 [email protected] ProteoNova™ Inc.